Tools for Practice Outils pour la pratique


#332 A Jab for Your CAD: Influenza vaccination for the prevention of cardiovascular events


CLINICAL QUESTION
QUESTION CLINIQUE
Does influenza vaccination reduce the risk of cardiovascular events?


BOTTOM LINE
RÉSULTAT FINAL
For every 100 patients vaccinated for influenza within about one month after an acute coronary syndrome, there will be 2 fewer cardiovascular events and 2 fewer deaths at one year compared to placebo. The impact of influenza vaccination in primary cardiovascular prevention and other cardiovascular conditions is less clear.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Five meta-analyses1-5 compared the effect of influenza vaccination to placebo/no vaccination on cardiovascular events (5-8 randomized controlled trials [RCTs], 4,211-12,029 patients, follow-up 1.5-12 months). Focusing on the most complete (results statistically significant unless otherwise stated):
  • Secondary prevention:
    • Influenza vaccination reduced the risk of all-cause mortality (relative risk reduction [RRR] 42%) and cardiovascular events (RRR 37%).1
      • Largest, highest-quality, multi-country (mostly European) RCT6 compared one-time influenza vaccination to placebo in 2,532 participants ≤3 days after myocardial infarction. At 1 year:
        • Death: 2.9% versus 4.9% with placebo.
        • Cardiovascular events (death, myocardial infarction, stent thrombosis): 5.3% versus 7.2% with placebo.
        • Local injection site reactions: ~5% absolute increase.
    • Limitations: Cardiovascular benefit only seen in patients within <2 months of acute coronary syndrome (unclear benefit in chronic coronary artery disease) in subgroup analysis.2
  • Other cardiovascular disease:7
    • Influenza vaccine did not reduce death or cardiovascular events in 2-year RCT of 5,129 patients with heart failure when compared to placebo but reduced overall hospitalization (15% versus 18% with placebo).
  • Primary prevention:3
    • No difference in cardiovascular deaths based on 12 events in 2 RCTs.
    • No other cardiovascular events reported.
  • No difference in cardiovascular events between: Different vaccine types/dose;8 or timing (administration during myocardial infarction hospitalization or within 30 days of discharge).

CONTEXT
CONTEXTE
  • Recent respiratory tract infections/influenza are associated with increased risk of cardiovascular events.10-11
  • Guidelines recommend influenza vaccination for people with coronary disease.12
  • ~40% of Canadian adults with a chronic condition receive influenza vaccination each year.13
  • Influenza vaccine efficacy for secondary cardiovascular prevention is comparable to other preventive therapies in reducing recurrent cardiovascular events [examples: Acetylsalicylic acid and statins (RRR ~25%)].14,15


Evelyn Westen January 23, 2023

this article confirmed my understanding of flu vax benefit and CV risk from influenza illness

Andrew Affleck January 23, 2023

subgroup analysis which sometimes creates bias, however good message is still vaccinating post MI is still beneficial

Donna Ward January 23, 2023

great support for advising to immunize!

Gilbert Bretecher March 6, 2023

Influenza vaccine reduces major Cv events within first year after acute coronary syndrome


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Blair J. MacDonald PharmD
  • Michael R. Kolber MSc MD CCFP
  • Ricky Turgeon BSc(Pharm) ACPR PharmD

1. Diaz-Arocutipa C, Saucedo-Chinchay J, Mamas MA, Vicent L. Travel Med Infect Dis. 2022;47:102311.

2. Behrouzi B, Bhatt DL, Cannon CP, et al. JAMA Netw Open. 2022; 5:e228873.

3. Clar C, Oseni Z, Flowers N, et al. Cochrane Database Syst Rev. 2015; 5:CD005050.

4. Udell JA, Zawi R, Bhatt DL, et al. JAMA. 2013; 310(16):1711-20.

5. Jaiswal V, Ang SP, Yaqoob S, et al. Eur J Prev Cardiol. 2022; 00:1-12.

6. Fröbert O, Götberg M, Erlinge D, et al. Circulation. 2021; 144(18):1476-84.

7. Loeb M, Roy A, Dokainish H, et al. Lancet Glob Health. 2022; 10:e1835-44.

8. Vardeny O, Kim K, Udell JA, et al. JAMA. 2021;325(1):39-49.

9. Fonseca HAR, Furtado RHM, Zimerman A, et al. Eur Heart J. 2022;43:4378-88.

10. Smeeth L, Thomas SL, Hall AJ, et al. N Engl J Med. 2004;351:2611-8.

11. Barnes M, Heywood AE, Mahimbo A, et al. Heart. 2015;101:1738-47.

12. Fihn SD, Gardin JM, Abrams J, et al. Circulation. 2012;126:3097-137.

13. Public Health Agency of Canada. Available at: https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022.html Accessed 2022 November 8.

14. Antithrombotic Trialists’ Collaboration. Lancet. 2009;373:1849-60.

15. Wilt TJ, Bloomfield HE, MacDonald R, et al. Arch Intern Med. 2004;164:1427-36.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.